Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence ...
PALO ALTO, Calif., Jan. 30, 2026 /PRNewswire/ -- Leading GMP cell therapy CDMO I Peace, Inc. (https://ipeace.com/en/), specializing in induced pluripotent stem cells ...
TOKYO & MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and ...
GRI Bio, Inc., a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, announced that the European Patent Office has ...
Phase I clinical trials, using αGalCer-loaded DCs to target iNKT cells, have shown promise in treating some patients with cancer. As humans have a low frequency of iNKT cells, therapies that combine ...
Researchers at UCLA have developed a powerful new weapon in the battle against kidney cancer. Instead of relying on treatments tailored to each patient, this innovation uses specially engineered ...
This post was updated March 31 at 11:21 p.m. UCLA researchers developed a human stem cell-derived cell therapy for an ...
UCLA researchers have developed a new kind of immunotherapy that harnesses the body’s immune system to fight cancer more effectively. The innovative cell therapy uses specially engineered immune cells ...
Mesothelin-targeted CAR-NKT cells leveraged three recognition mechanisms, potentially limiting antigen escape and immunoediting compared with single-pathway CAR-T constructs. Complete tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results